Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jacqueline, Gress"'
Autor:
Melissa Shaughnessy, J. Lalezari, Chloe Orkin, Josep Mallolas, Jacqueline Gress, Mark S. Sulkowski, Heather L. Platt, Christine Katlama, Mark T. Nelson, Mark Bloch, Jürgen K. Rockstroh, Philippe J. Zamor, Michael N. Robertson, Stephanie O. Klopfer, Bach-Yen Nguyen, Michael S. Saag, Eliav Barr, Janice Wahl, Gail V. Matthews
Publikováno v:
The Lancet HIV. 2:e319-e327
Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in patients with HIV-1. The C-EDGE CO-INFECTION study assessed the efficacy, safety, and tolerability of grazoprevir (MK-5172) plus elbasvir (MK-8742) in patients with HC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a207dd46c6d40cdc57b46e3f1ecc8da
https://doi.org/10.1016/s2352-3018(15)00114-9
https://doi.org/10.1016/s2352-3018(15)00114-9
Autor:
Eric Lawitz, Albrecht Stoehr, Maribel Rodriguez-Torres, Jacqueline Gress, Di An, Peggy Hwang, Richard J. O. Barnard, S. Bhanja, Lawrence Serfaty, Edward Gane, Niloufar Mobashery
Publikováno v:
Journal of Hepatology. 59:11-17
MK-7009 (vaniprevir) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. This report presents the primary analysis results (safety and sustained viral response) of a phase 2b study of MK-7009 given in combination w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7724bb0598f216f945dc5bd6c9814e35
https://doi.org/10.1016/j.jhep.2013.02.008
https://doi.org/10.1016/j.jhep.2013.02.008
Autor:
Edward Gane, Frank J. Dutko, Li Lin, Janice Wahl, Jacqueline Gress, Lisa Lupinacci, Stephen D. Shafran, Barbara Haber, Paul Y. Kwo, Maria Buti, John M. Vierling, Lawrence Serfaty, Stuart Black, Michael N. Robertson, Cheng Yuan Peng, Eliav Barr, Brian L. Pearlman, Paul Stryszak
Publikováno v:
Gastroenterology. 152(1)
Patients infected with hepatitis C virus (HCV) genotype 1, 4, or 6, with or without cirrhosis, previously treated with peg-interferon and ribavirin, are a challenge to treat. We performed a phase 3 randomized controlled open-label trial to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee29355301fb3e2909f139a9d373061
https://pubmed.ncbi.nlm.nih.gov/27720838
https://pubmed.ncbi.nlm.nih.gov/27720838
Autor:
Karen Eves, Florian Schödel, Henry R. Shinefield, Keith S. Reisinger, Steve Black, Barbara J. Kuter, Stephanie O. Klopfer, Laura Digilio, Mark M. Blatter, Michelle L Brown, Jacqueline Gress
Publikováno v:
Pediatric Infectious Disease Journal. 24:665-669
A quadrivalent measles, mumps, rubella and varicella vaccine would facilitate universal immunization against all 4 diseases, improve compliance and immunization rates and decrease the number of injections given to children and visits to physicians' o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5940a75775c55abb057c76427a39cc
https://doi.org/10.1097/01.inf.0000172902.25009.a1
https://doi.org/10.1097/01.inf.0000172902.25009.a1
Autor:
Yaacov Baruch, Savino Bruno, Patrick Marcellin, Niloufar Mobashery, John M. Vierling, Bruce R. Bacon, Michael P. Cooreman, Michael N. Robertson, Luzelena Caro, Peter M. Shaw, Christopher L. Gilbert, Peggy Hwang, Oren Shibolet, Janice Wahl, Christine Fandozzi, Michael P. Manns, Jacqueline Gress, Frank J. Dutko, Anita Y. M. Howe
Publikováno v:
Gastroenterology. 147(2)
Background & Aims MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97b904b6b2edfc91c6d2ffce5468f1d3
https://pubmed.ncbi.nlm.nih.gov/24727022
https://pubmed.ncbi.nlm.nih.gov/24727022
Autor:
Paul Y. Kwo, Jacqueline Gress, Cheng Yuan Peng, Lawrence Serfaty, Brian L. Pearlman, Lanjia Lin, Maria Buti, Michael N. Robertson, J. Vireling, E.J. Gane, Stephen D. Shafran, Barbara Haber, Paul Stryszak, Eliav Barr, Janice Wahl
Publikováno v:
Journal of Hepatology. 62:S674-S675
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd3065888b9431aefd8c6dc6ef86112e
https://doi.org/10.1016/s0168-8278(15)31088-6
https://doi.org/10.1016/s0168-8278(15)31088-6
Autor:
Stuart C. Gordon, Michelle Miller, Juergen K. Rockstroh, Richard J. O. Barnard, Luzelena Caro, Paul Y. Kwo, Benedict Maliakkal, Mark S. Sulkowski, Walter K. Kraft, Peggy Hwang, Eric Lawitz, Jacqueline Gress, Erin Quirk, Mohamed Al-Ibrahim, Ira M. Jacobson, Niloufar Mobashery, Paul Panorchan
Publikováno v:
Antiviral research. 99(3)
Vaniprevir is a competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease that has potent anti-HCV activity in preclinical models. This placebo-controlled dose-ranging study assessed the safety, tolerability, and antiviral efficacy of vani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80587a60436bfa50944480a4909c15f1
https://pubmed.ncbi.nlm.nih.gov/23747481
https://pubmed.ncbi.nlm.nih.gov/23747481
Publikováno v:
Expert Opinion on Investigational Drugs. 4:1313-1319
The safety/tolerability profile, immunogenicity and protective efficacy of VAQTA, Merck's hepatitis A vaccine, purified, inactivated, are based on studies of 18,239 vaccinees; 12,000 2–17 years and 6239 18 years and older. To date, no vaccinee has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2f8fa7494c7617fd137f81ba1b2ae01
https://doi.org/10.1517/13543784.4.12.1313
https://doi.org/10.1517/13543784.4.12.1313
Autor:
Heather L. Platt, Philippe J. Zamor, C. Orkin, Mark S. Sulkowski, Stephanie O. Klopfer, Gail V. Matthews, J. Lalezari, Juergen K. Rockstroh, Michael N. Robertson, Jacqueline Gress, Mark Bloch, Christine Katlama, Michael S. Saag, Josep Mallolas, Mark T. Nelson
Publikováno v:
Journal of Hepatology. 62:S675
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78db8783ab82e26f774fac6e73c3650c
https://doi.org/10.1016/s0168-8278(15)31089-8
https://doi.org/10.1016/s0168-8278(15)31089-8
Autor:
Michael N. Robertson, Maria Buti, John M. Vierling, Li Lin, Stephen D. Shafran, Barbara Haber, Jacqueline Gress, Eliav Barr, Paul Y. Kwo, Cheng Yuan Peng, Lawrence Serfaty, Brian L. Pearlman, Janice Wahl, Paul Stryszak, Edward Gane
Publikováno v:
Gastroenterology. 148:S-1194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7187258a7db0886667e24ef350cfbd53
https://doi.org/10.1016/s0016-5085(15)34080-4
https://doi.org/10.1016/s0016-5085(15)34080-4